메뉴 건너뛰기




Volumn 14, Issue 8, 2014, Pages

Anti-VEGF therapy for diabetic macular edema

Author keywords

Aflibercept; Bevacizumab; Diabetic macular edema; Pegaptanib; Ranibizumab; Vascular endothelial growth factor; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

EID: 84902022660     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0510-4     Document Type: Article
Times cited : (56)

References (72)
  • 1
    • 34848907420 scopus 로고    scopus 로고
    • Overview of epidemiologic studies of diabetic retinopathy
    • DOI 10.1080/09286580701396720, PII 782472822
    • Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179-83. (Pubitemid 47493723)
    • (2007) Ophthalmic Epidemiology , vol.14 , Issue.4 , pp. 179-183
    • Klein, B.E.K.1
  • 2
    • 84860218310 scopus 로고    scopus 로고
    • Global estimates of visual impairment: 2010
    • Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614-8.
    • (2012) Br J Ophthalmol , vol.96 , pp. 614-618
    • Pascolini, D.1    Mariotti, S.P.2
  • 3
    • 33746461855 scopus 로고    scopus 로고
    • Prevalence of diabetes and impaired fasting glucose in adults in the U.S. Population
    • Cowie C, Rust K, Byrd-Holt D, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care. 2006;29:1263-8.
    • (2006) Diabetes Care , vol.29 , pp. 1263-1268
    • Cowie, C.1    Rust, K.2    Byrd-Holt, D.3
  • 5
    • 77951089891 scopus 로고    scopus 로고
    • Brussels, Belgium: International Diabetes Federation, Accessed May 6, 2014
    • International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/ diabetesatlas. Accessed May 6, 2014.
    • (2013) IDF Diabetes Atlas, 6th Edn.
  • 7
    • 58149269716 scopus 로고    scopus 로고
    • Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050
    • Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126:1740-7.
    • (2008) Arch Ophthalmol , vol.126 , pp. 1740-1747
    • Saaddine, J.B.1    Honeycutt, A.A.2    Narayan, K.M.3    Zhang, X.4    Klein, R.5    Boyle, J.P.6
  • 10
    • 23244438018 scopus 로고    scopus 로고
    • Prevalence of diabetic retinopathy in urban India: The Chennai Urban Rural Epidemiology Study (CURES) Eye Study, I
    • DOI 10.1167/iovs.05-0019
    • Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328-33. (Pubitemid 43119476)
    • (2005) Investigative Ophthalmology and Visual Science , vol.46 , Issue.7 , pp. 2328-2333
    • Rema, M.1    Premkumar, S.2    Anitha, B.3    Deepa, R.4    Pradeepa, R.5    Mohan, V.6
  • 11
    • 58849099906 scopus 로고    scopus 로고
    • Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2
    • Raman R, Rani PK, Reddi Rachepalle S, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology. 2009;116:311-8.
    • (2009) Ophthalmology , vol.116 , pp. 311-318
    • Raman, R.1    Rani, P.K.2    Reddi Rachepalle, S.3
  • 12
    • 84857115824 scopus 로고    scopus 로고
    • Prevalence of diabetic macular oedema and related health and social care resource use in England
    • Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96:345-9.
    • (2012) Br J Ophthalmol , vol.96 , pp. 345-349
    • Minassian, D.C.1    Owens, D.R.2    Reidy, A.3
  • 13
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
    • Diabetes Control and Complications Trial Research Group
    • Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
    • (1993) N Engl J Med , vol.329 , pp. 977-986
  • 14
    • 0034628425 scopus 로고    scopus 로고
    • Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy
    • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-9.
    • (2000) N Engl J Med , vol.342 , pp. 381-389
  • 15
    • 0003573130 scopus 로고
    • Photocoagulation for diabeticmacular edema. ETDRS report No. 4
    • Early Treatment of Diabetic Retinopathy Study Research Group
    • Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabeticmacular edema. ETDRS report No. 4. Int Ophthalmol Clin 1987;27:265-272.
    • (1987) Int Ophthalmol Clin , vol.27 , pp. 265-272
  • 16
    • 0003680197 scopus 로고
    • Photocoagulation for diabeticmacular edema. ETDRS report No. 1
    • Early Treatment of Diabetic Retinopathy Study Research Group
    • Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabeticmacular edema. ETDRS report No. 1. Arch Ophthalmol 1985;103:1644-1652.
    • (1985) Arch Ophthalmol , vol.103 , pp. 1644-1652
  • 17
  • 18
    • 0030865278 scopus 로고    scopus 로고
    • Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway
    • Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 1997;273:H687-94.
    • (1997) Am J Physiol , vol.273
    • Bates, D.O.1    Curry, F.E.2
  • 19
    • 0029010434 scopus 로고
    • Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
    • Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369-79.
    • (1995) J Cell Sci , vol.108 , pp. 2369-2379
    • Roberts, W.G.1    Palade, G.E.2
  • 23
    • 0031126380 scopus 로고    scopus 로고
    • Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates
    • DOI 10.1006/exer.1996.0239
    • Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505-17. (Pubitemid 27321334)
    • (1997) Experimental Eye Research , vol.64 , Issue.4 , pp. 505-517
    • Ozaki, H.1    Hayashi, H.2    Vinores, S.A.3    Moromizato, Y.4    Campochiaro, P.A.5    Oshima, K.6
  • 25
    • 0043125643 scopus 로고    scopus 로고
    • 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization
    • 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483-9.
    • (2003) J Exp Med , vol.198 , pp. 483-489
    • Ishida, S.1    Usui, T.2    Yamashiro, K.3
  • 26
    • 0034979159 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
    • Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol. 2001;280:C1367-74. (Pubitemid 32553191)
    • (2001) American Journal of Physiology - Cell Physiology , vol.280 , Issue.6
    • Dor, Y.1    Porat, R.2    Keshet, E.3
  • 27
    • 0028815295 scopus 로고
    • Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization
    • Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905-9.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 905-909
    • Pierce, E.A.1    Avery, R.L.2    Foley, E.D.3
  • 28
    • 0029083832 scopus 로고
    • Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis
    • Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83-7.
    • (1995) FEBS Lett , vol.372 , pp. 83-87
    • Ben-Av, P.1    Crofford, L.J.2    Wilder, R.L.3    Hla, T.4
  • 29
    • 0032907687 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) and its receptors
    • Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22. (Pubitemid 29038270)
    • (1999) FASEB Journal , vol.13 , Issue.1 , pp. 9-22
    • Neufeld, G.1    Cohen, T.2    Gengrinovitch, S.3    Poltorak, Z.4
  • 30
    • 78049283701 scopus 로고    scopus 로고
    • Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab
    • Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30:1412-9.
    • (2010) Retina , vol.30 , pp. 1412-1419
    • Funk, M.1    Schmidinger, G.2    Maar, N.3
  • 31
    • 0036147042 scopus 로고    scopus 로고
    • Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema
    • DOI 10.1016/S0002-9394(01)01269-7, PII S0002939401012697
    • Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-7. (Pubitemid 34076505)
    • (2002) American Journal of Ophthalmology , vol.133 , Issue.1 , pp. 70-77
    • Funatsu, H.1    Yamashita, H.2    Noma, H.3    Mimura, T.4    Yamashita, T.5    Hori, S.6
  • 33
    • 1542742166 scopus 로고    scopus 로고
    • Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412
    • DOI 10.1167/iovs.03-0955
    • Campochiaro PA. C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922-31. (Pubitemid 38868393)
    • (2004) Investigative Ophthalmology and Visual Science , vol.45 , Issue.3 , pp. 922-931
    • Campochiaro, P.A.1
  • 34
    • 0032493654 scopus 로고    scopus 로고
    • 165): Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
    • DOI 10.1074/jbc.273.32.20556
    • Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF-165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon7-encoded domain. J Biol Chem. 1998;273:20556-67. (Pubitemid 28377626)
    • (1998) Journal of Biological Chemistry , vol.273 , Issue.32 , pp. 20556-20567
    • Ruckman, J.1    Green, L.S.2    Beeson, J.3    Waugh, S.4    Gillette, W.L.5    Henninger, D.D.6    Claesson-Welsh, L.7    Janjic, N.8
  • 35
    • 84865129521 scopus 로고    scopus 로고
    • Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
    • Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171-85.
    • (2012) Angiogenesis , vol.15 , pp. 171-185
    • Papadopoulos, N.1    Martin, J.2    Ruan, Q.3
  • 36
    • 33749632278 scopus 로고    scopus 로고
    • Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    • DOI 10.1097/01.iae.0000242842.14624.e7, PII 0000698220061000000002
    • Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-70. (Pubitemid 44547437)
    • (2006) Retina , vol.26 , Issue.8 , pp. 859-870
    • Ferrara, N.1    Damico, L.2    Shams, N.3    Lowman, H.4    Kim, R.5
  • 37
  • 39
    • 84867096307 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema
    • Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema. Ophthalmology. 2012;119:2179-88.
    • (2012) Ophthalmology , vol.119 , pp. 2179-2188
    • Ho, A.C.1    Scott, I.U.2    Kim, S.J.3
  • 40
    • 79953311138 scopus 로고    scopus 로고
    • Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
    • The RESTORE Study. This phase III trial demonstrated that ranibizumab with or without laser photocoagulation significantly improves vision more than laser photocoagulation
    • .•• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25. This phase III trial demonstrated that ranibizumab with or without laser photocoagulation significantly improves vision more than laser photocoagulation.
    • (2011) Ophthalmology , vol.118 , pp. 615-625
    • Mitchell, P.1    Bandello, F.2    Schmidt-Erfurth, U.3
  • 41
    • 77952779304 scopus 로고    scopus 로고
    • Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network
    • Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-77.
    • (2010) Ophthalmology , vol.117 , pp. 1064-1077
    • Elman, M.J.1    Aiello, L.P.2    Beck, R.W.3
  • 42
    • 79953299899 scopus 로고    scopus 로고
    • Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    • Diabetic Retinopathy Clinical Research Network. This phase III trial demonstrated that ranibizumab with prompt or deferred laser photocoagulation improves vision more than that laser photocoagulation or intraocular triamcinolone with laser
    • .•• Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14. This phase III trial demonstrated that ranibizumab with prompt or deferred laser photocoagulation improves vision more than that laser photocoagulation or intraocular triamcinolone with laser.
    • (2011) Ophthalmology , vol.118 , pp. 609-614
  • 43
    • 84863401792 scopus 로고    scopus 로고
    • Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE
    • RISE and RIDE Research Group. This phase III trial demonstrated that monthly administration of two doses of ranibizumab (0.3 mg and 0.5 mg) over 2 years produces superior vision and macular thinning compared to laser, and frequently improves the severity of the retinopathy
    • .•• Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801. This phase III trial demonstrated that monthly administration of two doses of ranibizumab (0.3 mg and 0.5 mg) over 2 years produces superior vision and macular thinning compared to laser, and frequently improves the severity of the retinopathy.
    • (2012) Ophthalmology , vol.119 , pp. 789-801
    • Nguyen, Q.D.1    Brown, D.M.2    Marcus, D.M.3
  • 44
    • 79958012399 scopus 로고    scopus 로고
    • Ice KS for the Macugen 1013 Study Group. A phase 2/3, multi-center, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema
    • Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS for the Macugen 1013 Study Group. A phase 2/3, multi-center, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118:1107-18.
    • (2011) Ophthalmology , vol.118 , pp. 1107-1118
    • Sultan, M.B.1    Zhou, D.2    Loftus, J.3    Dombi, T.4
  • 45
    • 84904390116 scopus 로고    scopus 로고
    • Regeneron Press Release: Accessed February 24, 2014
    • Regeneron Press Release: http://investor.regeneron.com/releasedetail.cfm? releaseid=782911. Accessed February 24, 2014.
  • 46
    • 25844513658 scopus 로고    scopus 로고
    • A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
    • Cunningham Jr ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747-57.
    • (2005) Ophthalmology , vol.112 , pp. 1747-1757
    • Cunningham Jr., E.T.1    Adamis, A.P.2    Altaweel, M.3
  • 47
    • 33845191304 scopus 로고    scopus 로고
    • Vascular endothelial growth factor is a critical stimulus for diabetic macular edema
    • Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-9.
    • (2006) Am J Ophthalmol , vol.142 , pp. 961-969
    • Nguyen, Q.D.1    Tatlipinar, S.2    Shah, S.M.3
  • 48
    • 33748957021 scopus 로고    scopus 로고
    • A Pilot Study of Multiple Intravitreal Injections of Ranibizumab in Patients with Center-Involving Clinically Significant Diabetic Macular Edema
    • DOI 10.1016/j.ophtha.2006.04.033, PII S0161642006007445
    • Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology. 2006;113:1706-12. (Pubitemid 44442451)
    • (2006) Ophthalmology , vol.113 , Issue.10 , pp. 1706-1712
    • Chun, D.W.1    Heier, J.S.2    Topping, T.M.3    Duker, J.S.4    Bankert, J.M.5
  • 49
    • 70350567637 scopus 로고    scopus 로고
    • Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study
    • Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175-81.
    • (2009) Ophthalmology , vol.116 , pp. 2175-2181
    • Nguyen, Q.D.1    Shah, S.M.2    Heier, J.S.3
  • 50
    • 78049293726 scopus 로고    scopus 로고
    • Two-year outcomes of ranibizumab for edema of the macula in diabetes (READ-2) study
    • Nguyen QD, Shan SM, Khwaja AA, et al. Two-year outcomes of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51.
    • (2010) Ophthalmology , vol.117 , pp. 2146-2151
    • Nguyen, Q.D.1    Shan, S.M.2    Khwaja, A.A.3
  • 51
    • 84874080959 scopus 로고    scopus 로고
    • Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged treatment
    • Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged treatment. JAMA Ophthalmol. 2013;131:139-45.
    • (2013) JAMA Ophthalmol , vol.131 , pp. 139-145
    • Do, D.V.1    Nguyen, Q.D.2    Khwaja, A.A.3
  • 52
    • 84885022258 scopus 로고    scopus 로고
    • Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials
    • Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology. 2013;120:2013-22.
    • (2013) Ophthalmology , vol.120 , pp. 2013-2022
    • Brown, D.M.1    Nguyen, Q.D.2    Marcus, D.M.3
  • 53
    • 79251606719 scopus 로고    scopus 로고
    • Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study)
    • Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care. 2010;33:2399-405.
    • (2010) Diabetes Care , vol.33 , pp. 2399-2405
    • Massin, P.1    Bandello, F.2    Garweg, J.G.3
  • 54
    • 84885022310 scopus 로고    scopus 로고
    • Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE extension study
    • Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013;120:2004-12.
    • (2013) Ophthalmology , vol.120 , pp. 2004-2012
    • Lang, G.E.1    Berta, A.2    Eldem, B.M.3
  • 55
    • 77952762919 scopus 로고    scopus 로고
    • A new approach to the management of diabetic macular edema
    • [Editorial]
    • Schachat SP. A new approach to the management of diabetic macular edema [Editorial]. Ophthalmology. 2013;117:1059-60.
    • (2013) Ophthalmology , vol.117 , pp. 1059-1060
    • Schachat, S.P.1
  • 56
    • 82755164498 scopus 로고    scopus 로고
    • Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema
    • Diabetes Retinopathy Clinical Research Network
    • Diabetes Retinopathy Clinical Research Network, Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5-e14.
    • (2011) Ophthalmology , vol.118
    • Aiello, L.P.1    Beck, R.W.2    Bressler, N.M.3
  • 57
    • 34748876124 scopus 로고    scopus 로고
    • A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
    • Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-7.
    • (2007) Ophthalmology , vol.114 , pp. 1860-1867
    • Scott, I.U.1    Edwards, A.R.2    Beck, R.W.3
  • 58
    • 77952889192 scopus 로고    scopus 로고
    • A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2
    • Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-86.
    • (2010) Ophthalmology , vol.117 , pp. 1078-1086
    • Michaelides, M.1    Kaines, A.2    Hamilton, R.D.3
  • 59
    • 84865593623 scopus 로고    scopus 로고
    • A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: Report 3
    • This 2-year trial demonstrated that bevacizumab is superior to laser photocoagulation
    • .• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972-9. This 2-year trial demonstrated that bevacizumab is superior to laser photocoagulation.
    • (2012) Arch Ophthalmol , vol.130 , pp. 972-979
    • Rajendram, R.1    Fraser-Bell, S.2    Kaines, A.3
  • 60
    • 67349168190 scopus 로고    scopus 로고
    • Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema
    • Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142-450.
    • (2009) Ophthalmology , vol.116 , pp. 1142-1450
    • Soheilian, M.1    Ramezani, A.2    Obudi, A.3
  • 61
    • 84856598999 scopus 로고    scopus 로고
    • Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema
    • Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012;32:314-21.
    • (2012) Retina , vol.32 , pp. 314-321
    • Soheilian, M.1    Garfami, K.H.2    Ramezani, A.3    Yaseri, M.4    Peyman, G.A.5
  • 62
    • 68049148355 scopus 로고    scopus 로고
    • Primary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 months
    • Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116:1488-97.
    • (2009) Ophthalmology , vol.116 , pp. 1488-1497
    • Arevalo, J.F.1    Sanchez, J.G.2    Wu, L.3
  • 63
    • 60849129118 scopus 로고    scopus 로고
    • An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema
    • Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93:114-49.
    • (2009) Br J Ophthalmol , vol.93 , pp. 114-149
    • Do, D.V.1    Nguyen, Q.D.2    Shah, S.M.3
  • 64
    • 84864444516 scopus 로고    scopus 로고
    • One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema
    • This 1-year trial demonstrated that monthly or bimonthly aflibercept is superior to laser photocoagulation
    • .• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-65. This 1-year trial demonstrated that monthly or bimonthly aflibercept is superior to laser photocoagulation.
    • (2012) Ophthalmology , vol.119 , pp. 1658-1665
    • Do, D.V.1    Nguyen, Q.D.2    Boyer, D.3
  • 65
    • 84875242688 scopus 로고    scopus 로고
    • Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase 1/2 study
    • Campochiaro PA, Chaana R, Berger B, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase 1/2 study. Am J Ophthalmol. 2013;155:697-704.
    • (2013) Am J Ophthalmol , vol.155 , pp. 697-704
    • Campochiaro, P.A.1    Chaana, R.2    Berger, B.3
  • 66
    • 84904390117 scopus 로고    scopus 로고
    • Accessed February 25, 2014
    • http://www.thepharmaletter.com/article/uk-s-nice-backs-use-of-novartis- lucentis-for-diabetic-macular-edema. Accessed February 25, 2014.
  • 67
    • 84882254907 scopus 로고    scopus 로고
    • A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema
    • Nepomuceno AB, Takaki E, de Almeida FP P, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156:502-10.
    • (2013) Am J Ophthalmol , vol.156 , pp. 502-510
    • Nepomuceno, A.B.1    Takaki, E.2    De Almeida, F.P.P.3
  • 71
    • 84860218792 scopus 로고    scopus 로고
    • Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: Evidence from the RESTORE trial
    • Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96:688-93.
    • (2012) Br J Ophthalmol , vol.96 , pp. 688-693
    • Mitchell, P.1    Annemans, L.2    Gallagher, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.